| Recruiting | Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/P NCT07227571 | Fred Hutchinson Cancer Center | Phase 1 |
| Not Yet Recruiting | IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma NCT06412458 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation NCT06041490 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic O NCT05019703 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas NCT05515068 | Klinikum Stuttgart | — |
| Suspended | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Youn NCT04539366 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or R NCT04751383 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Suspended | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma NCT04616560 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma NCT04668300 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarc NCT03598595 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Ca NCT03449108 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors NCT03320330 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma NCT02487979 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma NCT02484443 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma NCT02470091 | Children's Oncology Group | Phase 2 |
| Active Not Recruiting | Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in th NCT02502786 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone NCT02357810 | Northwestern University | Phase 2 |
| Active Not Recruiting | Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma NCT02243605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma NCT02097238 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02011126 | Children's Oncology Group | Phase 2 |
| Completed | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma NCT01614795 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma NCT01374672 | Children's Oncology Group | — |
| Completed | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01154816 | Children's Oncology Group | Phase 2 |
| Completed | DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma NCT01190943 | Children's Oncology Group | — |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue NCT01016015 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas NCT01807052 | Children's Oncology Group | — |
| Completed | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery NCT01553539 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors NCT00831844 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Blood Samples From Patients With Osteosarcoma NCT00954473 | Children's Oncology Group | — |
| Completed | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) NCT00330421 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Young Patients With Refractory Solid Tumors NCT00331643 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors NCT00093821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood NCT00030667 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |